2026 Q2 - tulosraportti
51 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 64 | - | - | ||
| 1 400 | - | - | ||
| 14 | - | - | ||
| 1 | - | - | ||
| 521 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
2 t sittenAfter fall I thought i buy more when the stock goes under 10kr, I'm surprised it has not been happened, or has been very close but yeah, not. People Have calmed down, but it is still possible that good news take so long that this will dip a little bit more, or rise soon. But I'm sitting Well, other account has this stock something like +700%.
·3 t sittenCircio and in vivo CAR-T – how far have they actually come? (1/5) We have previously touched upon DNA formats like nanoSMAR and C4DNA, and various delivery systems Circio is testing. I wanted to take a closer look at a slightly different question before ESGCT: What has Circio actually shown within CAR-T, and what distinguishes this from what other researchers have already achieved? This is a review of publicly available trials and studies, not independent research. I find the possibilities interesting, but it is still quite a long way from promising gene expression to a functioning treatment. First, briefly about the idea itself. CAR-T entails equipping T-cells with an artificial receptor that can recognize a specific target, for example CD19 on B-cells or BCMA on myeloma cells. Usually, the T-cells are harvested from the patient, genetically modified in a laboratory, and given back. This is a treatment that can be very effective in certain blood cancers, but production is complicated. With in vivo CAR-T, one attempts to program the T-cells directly inside the body. This potentially avoids parts of the individual cell manufacturing process. The challenge is to get the genetic instructions into exactly the right cells and make them produce a functioning CAR. This is where circVec comes in. It is not a finished dose of circular RNA, but a DNA cassette intended to make the cell itself produce circular RNA and subsequently protein: circVec-DNA → circular RNA → CAR-protein. Circular RNA differs from ordinary linear mRNA in that it lacks free ends. This can make the RNA more resistant to certain degradation mechanisms and thus provide longer expression. However, just how large this advantage actually turns out to be in activated T-cells remains to be documented. Circio's thought is that this can provide a longer expression window than directly delivered mRNA, without being designed for permanent integration into the genome like lentiviral CAR systems are. It is precisely this space that I find interesting. A short RNA treatment may be sufficient in certain autoimmune diseases, whereas treating cancer may place different demands on duration. At the same time, the longest possible CAR expression is not automatically the best; risk and control must also be evaluated. What I am therefore trying to figure out through this series is whether circVec can become more than a technology that produces light from mouse tissue over a long period. Can it actually program T-cells, and do so in a way that has an advantage compared to the methods competitors are developing? First, we must look at Circio's own figures from September 1. Several sources and links will come in part 5.
·3 t sittenI have a feeling many are holding long-term. And brokerage houses have managed to push the price down by selling back and forth between each other's accounts. I think that the 5kr can bounce back quickly if there is any sign of a good result. To me it seems like wiklund is good at not saying more than he has to. Something that benefits us 27-28
43 min sittenWiklund know how to milk cows , when we rich 14-15 kr per share they doing issue, that's mean share price is high enough
·4 t sittenStill plenty of time to top up before it gets too late
For sent? It is so foolish to come with something like that. As long as the stock is listed, it can be bought. If one thinks it e.g. will go up to 50 or 100kr, then it is idiotic to think about these small changes in the share price
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
51 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 2 t sittenAfter fall I thought i buy more when the stock goes under 10kr, I'm surprised it has not been happened, or has been very close but yeah, not. People Have calmed down, but it is still possible that good news take so long that this will dip a little bit more, or rise soon. But I'm sitting Well, other account has this stock something like +700%.
- ·3 t sittenCircio and in vivo CAR-T – how far have they actually come? (1/5) We have previously touched upon DNA formats like nanoSMAR and C4DNA, and various delivery systems Circio is testing. I wanted to take a closer look at a slightly different question before ESGCT: What has Circio actually shown within CAR-T, and what distinguishes this from what other researchers have already achieved? This is a review of publicly available trials and studies, not independent research. I find the possibilities interesting, but it is still quite a long way from promising gene expression to a functioning treatment. First, briefly about the idea itself. CAR-T entails equipping T-cells with an artificial receptor that can recognize a specific target, for example CD19 on B-cells or BCMA on myeloma cells. Usually, the T-cells are harvested from the patient, genetically modified in a laboratory, and given back. This is a treatment that can be very effective in certain blood cancers, but production is complicated. With in vivo CAR-T, one attempts to program the T-cells directly inside the body. This potentially avoids parts of the individual cell manufacturing process. The challenge is to get the genetic instructions into exactly the right cells and make them produce a functioning CAR. This is where circVec comes in. It is not a finished dose of circular RNA, but a DNA cassette intended to make the cell itself produce circular RNA and subsequently protein: circVec-DNA → circular RNA → CAR-protein. Circular RNA differs from ordinary linear mRNA in that it lacks free ends. This can make the RNA more resistant to certain degradation mechanisms and thus provide longer expression. However, just how large this advantage actually turns out to be in activated T-cells remains to be documented. Circio's thought is that this can provide a longer expression window than directly delivered mRNA, without being designed for permanent integration into the genome like lentiviral CAR systems are. It is precisely this space that I find interesting. A short RNA treatment may be sufficient in certain autoimmune diseases, whereas treating cancer may place different demands on duration. At the same time, the longest possible CAR expression is not automatically the best; risk and control must also be evaluated. What I am therefore trying to figure out through this series is whether circVec can become more than a technology that produces light from mouse tissue over a long period. Can it actually program T-cells, and do so in a way that has an advantage compared to the methods competitors are developing? First, we must look at Circio's own figures from September 1. Several sources and links will come in part 5.
- ·3 t sittenI have a feeling many are holding long-term. And brokerage houses have managed to push the price down by selling back and forth between each other's accounts. I think that the 5kr can bounce back quickly if there is any sign of a good result. To me it seems like wiklund is good at not saying more than he has to. Something that benefits us 27-2843 min sittenWiklund know how to milk cows , when we rich 14-15 kr per share they doing issue, that's mean share price is high enough
- ·4 t sittenStill plenty of time to top up before it gets too lateFor sent? It is so foolish to come with something like that. As long as the stock is listed, it can be bought. If one thinks it e.g. will go up to 50 or 100kr, then it is idiotic to think about these small changes in the share price
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 64 | - | - | ||
| 1 400 | - | - | ||
| 14 | - | - | ||
| 1 | - | - | ||
| 521 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
51 päivää sitten
‧51 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 15.4.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- 2 t sittenAfter fall I thought i buy more when the stock goes under 10kr, I'm surprised it has not been happened, or has been very close but yeah, not. People Have calmed down, but it is still possible that good news take so long that this will dip a little bit more, or rise soon. But I'm sitting Well, other account has this stock something like +700%.
- ·3 t sittenCircio and in vivo CAR-T – how far have they actually come? (1/5) We have previously touched upon DNA formats like nanoSMAR and C4DNA, and various delivery systems Circio is testing. I wanted to take a closer look at a slightly different question before ESGCT: What has Circio actually shown within CAR-T, and what distinguishes this from what other researchers have already achieved? This is a review of publicly available trials and studies, not independent research. I find the possibilities interesting, but it is still quite a long way from promising gene expression to a functioning treatment. First, briefly about the idea itself. CAR-T entails equipping T-cells with an artificial receptor that can recognize a specific target, for example CD19 on B-cells or BCMA on myeloma cells. Usually, the T-cells are harvested from the patient, genetically modified in a laboratory, and given back. This is a treatment that can be very effective in certain blood cancers, but production is complicated. With in vivo CAR-T, one attempts to program the T-cells directly inside the body. This potentially avoids parts of the individual cell manufacturing process. The challenge is to get the genetic instructions into exactly the right cells and make them produce a functioning CAR. This is where circVec comes in. It is not a finished dose of circular RNA, but a DNA cassette intended to make the cell itself produce circular RNA and subsequently protein: circVec-DNA → circular RNA → CAR-protein. Circular RNA differs from ordinary linear mRNA in that it lacks free ends. This can make the RNA more resistant to certain degradation mechanisms and thus provide longer expression. However, just how large this advantage actually turns out to be in activated T-cells remains to be documented. Circio's thought is that this can provide a longer expression window than directly delivered mRNA, without being designed for permanent integration into the genome like lentiviral CAR systems are. It is precisely this space that I find interesting. A short RNA treatment may be sufficient in certain autoimmune diseases, whereas treating cancer may place different demands on duration. At the same time, the longest possible CAR expression is not automatically the best; risk and control must also be evaluated. What I am therefore trying to figure out through this series is whether circVec can become more than a technology that produces light from mouse tissue over a long period. Can it actually program T-cells, and do so in a way that has an advantage compared to the methods competitors are developing? First, we must look at Circio's own figures from September 1. Several sources and links will come in part 5.
- ·3 t sittenI have a feeling many are holding long-term. And brokerage houses have managed to push the price down by selling back and forth between each other's accounts. I think that the 5kr can bounce back quickly if there is any sign of a good result. To me it seems like wiklund is good at not saying more than he has to. Something that benefits us 27-2843 min sittenWiklund know how to milk cows , when we rich 14-15 kr per share they doing issue, that's mean share price is high enough
- ·4 t sittenStill plenty of time to top up before it gets too lateFor sent? It is so foolish to come with something like that. As long as the stock is listed, it can be bought. If one thinks it e.g. will go up to 50 or 100kr, then it is idiotic to think about these small changes in the share price
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 64 | - | - | ||
| 1 400 | - | - | ||
| 14 | - | - | ||
| 1 | - | - | ||
| 521 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt